Results 211 to 220 of about 190,185 (400)

Management of Breakthrough Bleeding During Emicizumab Prophylaxis in Acquired Haemophilia A: Data From the GTH‐AHA‐EMI Study

Haemophilia, EarlyView.
ABSTRACT Introduction The GTH‐AHA‐EMI study showed that emicizumab reduces bleeding in patients with acquired haemophilia A (AHA). However, 22 clinically relevant new bleeds (CRNB) occurred in 14 of the 47 study patients, most of which required haemostatic treatment.
Halet Türkantoz, Christiane Dobbelstein, Richard Greil, Christina Hart, Robert Klamroth, Paul Knöbl, Johannes Oldenburg, Christian Pfrepper, Ulrich Sachs, Inga M. Schimansky, Karolin Trautmann‐Grill, Andreas Tiede   +11 more
wiley   +1 more source

Impact of Advanced Maternal Age on Laboratory Markers in Preeclamptic Pregnancies: A Cross-Sectional Study. [PDF]

Obstet Gynecol Int
Arstanalievna SG, Singh P, Khan S, Abdivalievna SN, Yrysbaevich YE, Yrysbaevich YA.   +5 more
europepmc   +1 more source

Comparing prothrombin complex concentrate and fresh frozen plasma with blood viscosity characteristics in patients with trauma-induced coagulopathy [PDF]

, 2015
О. О. Тарабрін, I. I. Tyutrin, S Shcherbakov, D. Gavrychenko, G. Mazurenko, В. О. Іванова, P. Tarabrin   +6 more
openalex   +1 more source

Effective Reversal of Edoxaban-associated Bleeding with Four-factor Prothrombin Complex Concentrate in a Rabbit Model of Acute Hemorrhage

Anesthesiology, 2015
E. Herzog, F. Kaspereit, Wilfried Krege, Baerbel Doerr, Jochen Mueller-Cohrs, I. Pragst, Y. Morishima, G. Dickneite   +7 more
semanticscholar   +1 more source

The Measurement of Prothrombin in Plasma [PDF]

Journal of Clinical Pathology, 1953
R, BIGGS, A S, DOUGLAS
openaire   +2 more sources

Clinical Significance of Anti‐Atezolizumab Antibodies in Patients With Unresectable Hepatocellular Carcinoma Treated With Atezolizumab Plus Bevacizumab

Hepatology Research, EarlyView.
ABSTRACT Aim Systemic therapy is required for unresectable hepatocellular carcinoma (HCC). Atezolizumab plus bevacizumab (ATZ/BEV) is the recommended first‐line treatment for HCC; however, the development of anti‐drug antibodies (ADAs) against ATZ may impair its therapeutic efficacy. Although ADAs have been reported in other cancers treated with immune
Keishi Ouchi, Jun Inoue, Masashi Ninomiya, Mio Tsuruoka, Kosuke Sato, Kotaro Doi, Kengo Watanabe, Tomoya Sasazaki, Atsushi Masamune   +8 more
wiley   +1 more source

Predictive value of the prothrombin time-to-albumin ratio for 28- and 90-day mortality in lung cancer patients admitted to the intensive care unit: A retrospective cohort study. [PDF]

Medicine (Baltimore)
Jia F, Xia G, Xu T, Hu L, Wu S, Liu L, Lei X.   +6 more
europepmc   +1 more source

Role of prothrombin complex concentrate in the severe trauma patient

Frontiers in Medicine, 2022
Juan José Egea-Guerrero, Juan José Egea-Guerrero, Manuel Quintana-Diaz   +2 more
doaj   +1 more source

Impact of Treatment Response to Anticoagulant Therapy on Liver‐Related Events in Patients With Cirrhosis and Portal Vein Thrombosis

Hepatology Research, EarlyView.
In patients with cirrhosis and a first portal vein thrombosis treated with intravenous anticoagulant therapy, the 3‐year cumulative rates of liver‐related events were 56.7% and 75.5% in the effective and ineffective groups, respectively. A good radiological response was associated with fewer liver‐related hospitalizations.
Atsushi Maeda, Yuki Tahata, Hayato Hikita, Hisashi Ishida, Takayuki Yakushijin, Masanori Nakahara, Kazuyoshi Ohkawa, Fumihiko Nakanishi, Sadaharu Iio, Ryotaro Sakamori, Mitsuru Sakakibara, Masanori Miyazaki, Yuta Myoin, Kazuki Maesaka, Kumiko Shirai, Kazuhiro Murai, Yuki Makino, Yoshinobu Saito, Takahiro Kodama, Tetsuo Takehara   +19 more
wiley   +1 more source

Bothrops jararaca snake venom: A reappraisal of its coagulant activity in humans, mice, and rats. [PDF]

PLoS Negl Trop Dis
Torres AV, Penas Picon NT, Ferreira de Oliveira N, Sachetto ATA, Thomazini CM, de Albuquerque CZ, Mattaraia VGM, Santoro ML.   +7 more
europepmc   +1 more source